IADR Abstract Archives
Occlusal Splint or Botulinum Toxin-a for jaw Muscle Pain Treatment: a Randomized Controlled Trial
Objectives: To conduct a randomized controlled trial comparing the effect of occlusal splint and botulinum toxin-A on jaw muscle pain resulting from probable bruxism.
Methods: Sixty patients were randomly allocated into two intervention groups. The primary outcome was the reduction of jaw muscle pain assessed by the Graded Chronic Pain Scale (v2.0) (GCPS). Secondary outcomes were also assessed: Parameters of jaw opening and mandibular mobility; Distribution of muscle pain; Jaw Functional Limitation Scale–20 (JFLS-20), Oral Behaviors Checklist (OBC), and Oral Health Impact Profile-14 (OHIP-14). Multilevel mixed-effects regression models were used to analyze the data.
Results: Fifty-nine patients (30 received occlusal splint and 29 botulinum toxin-A) were analyzed at baseline, 3 and 6 months follow-up. No differences between the interventions were observed concerning the GCPS (p=0.627), although a significant reduction was observed at 3 (IOR=13.26, 95%CI[6.61–26.59]) and 6 months (IOR=12.36, 95%CI [4.93–30.98]). Botulin toxin-A shows a lower score reduction on JFLS-20 than occlusal splint (IOR=0.29, 95%CI[0.11–0.82]). Botulinum toxin-A presented inferior results for the parameters: opening without pain (p=0.045), unassisted maximum opening (p=0.024), assisted maximum opening (p=0.041), and protrusion (0.016). An improvement in OHIP-14 scores was observed at 3 (IRR=1.08, CI95%[1.02–1.14]) and 6 months (IRR=1.10, CI95%[1.04–1.16]), regardless of intervention.
Conclusions: The findings indicate that occlusal splint and Botulinum toxin-A can effectively decrease the scores of the Graded Chronic Pain Scale, improve OHRQoL, and enhance functional outcomes in bruxist patients with jaw muscle pain. Occlusal splint demonstrated slight advantages in specific parameters.
Methods: Sixty patients were randomly allocated into two intervention groups. The primary outcome was the reduction of jaw muscle pain assessed by the Graded Chronic Pain Scale (v2.0) (GCPS). Secondary outcomes were also assessed: Parameters of jaw opening and mandibular mobility; Distribution of muscle pain; Jaw Functional Limitation Scale–20 (JFLS-20), Oral Behaviors Checklist (OBC), and Oral Health Impact Profile-14 (OHIP-14). Multilevel mixed-effects regression models were used to analyze the data.
Results: Fifty-nine patients (30 received occlusal splint and 29 botulinum toxin-A) were analyzed at baseline, 3 and 6 months follow-up. No differences between the interventions were observed concerning the GCPS (p=0.627), although a significant reduction was observed at 3 (IOR=13.26, 95%CI[6.61–26.59]) and 6 months (IOR=12.36, 95%CI [4.93–30.98]). Botulin toxin-A shows a lower score reduction on JFLS-20 than occlusal splint (IOR=0.29, 95%CI[0.11–0.82]). Botulinum toxin-A presented inferior results for the parameters: opening without pain (p=0.045), unassisted maximum opening (p=0.024), assisted maximum opening (p=0.041), and protrusion (0.016). An improvement in OHIP-14 scores was observed at 3 (IRR=1.08, CI95%[1.02–1.14]) and 6 months (IRR=1.10, CI95%[1.04–1.16]), regardless of intervention.
Conclusions: The findings indicate that occlusal splint and Botulinum toxin-A can effectively decrease the scores of the Graded Chronic Pain Scale, improve OHRQoL, and enhance functional outcomes in bruxist patients with jaw muscle pain. Occlusal splint demonstrated slight advantages in specific parameters.